The third International Stroke Trial (IST-3) is the largest (n=3035) randomised controlled trial of intravenous alteplase for acute ischaemic stroke to date. Participants in IST-3 were older than in previous trials: 1617 (53%) were older than 80 years of age, whereas only 112 patients of this age were included in eight previous similar trials. 2 In IST-3, participants could be treated up to 6 h after stroke onset, but 849 (28%) were treated within 3 h. No signifi cant eff ect of alteplase was reported on the IST-3 primary endpoint-independence at 6 months (defi ned as an Oxford Handicap Scale score of 0-2). However, in a prespecifi ed ordinal analysis, a signifi cant shift was noted in functional outcome, in favour of alteplase.
1 A meta-analysis of individual patient data from nine randomised trials (including IST-3) showed that intravenous alteplase improved outcome when administered up to 4·5 h after stroke onset. 2 The proportional benefi t from alteplase increased with earlier treatment but was not modifi ed by age.
2 IST-3 is a landmark study because the eff ects of alteplase could be assessed reliably in older patients with acute ischaemic stroke.
investigators, and this study includes a large population of patients with ALS and has a rigorous design. However, the same results need to be attained by less skilled investigators than those involved in this study, and the worldwide application of the technique will depend on the acquisition of new equipment and software. However, the study undoubtedly shows that detection of increased cortical excitability is a diagnostic biomarker in ALS, and that use of threshold tracking TMS with existing criteria might help to speed up the process of diagnosis. 1, 3 Nonetheless, despite these promising results, the question of disease onset is not yet resolved. Early signs of hyperexcitability are seen in the LMN pool; the presence of fasciculation potentials is the fi rst change detected in clinically non-aff ected muscles of patients with ALS.
9 This fi nding could be attributed to LMN activation due to increased cortical drive, but not all fasciculation potentials seen in the strong muscles of ALS patients originate in the anterior horn cell. Signs of corticomotoneuronal abnormality, as assessed by threshold tracking TMS, have been reported to precede signs of LMN dysfunction in the target muscle. Altogether, we cannot reject the possibility that increased corticomotor excitability early in the disease course is a non-localised event in ALS and other neurodegenerative disorders associated with reduced GABA, 10 whereas LMN degeneration is a topographic occurrence, fi rstly aff ecting a specifi c region before spreading to other areas.
9
Electromyography is sensitive for diagnosis of ALS independent of the LMN or UMN disease origin; 9 the same holds true for threshold tracking TMS.
1 Early diagnosis of ALS and use of neurophysiology as a surrogate marker to detect changes in exploratory clin ical trials are imperative. Other groups should apply this technique in diagnosis of ALS. However, the mystery of the disease's origin remains and demands further research. Joanna Wardlaw and colleagues in the IST-3 collaborative group report in The Lancet Neurology their fi ndings on brain imaging.
Mamede de Carvalho
3 They sought to establish whether early ischaemic or pre-existing CT signs were associated with the eff ect of alteplase on several outcomes, including symptomatic intracerebral haemorrhage and independence at 6 months. All images were reviewed centrally. Early ischaemic changes were classifi ed as hyperattenuated artery, tissue hypoattenuation, and ischaemic lesion swelling, and infarct extent was also assessed; pre-existing signs were classifi ed as old infarcts, leukoaraiosis, and brain atrophy. Diminished independent survival was associated with all early ischaemic changes (including tissue hypoattenuation [odds ratio 0·66, 95% CI 0·55-0·81]), leukoaraiosis (0·72, 0·59-0·87), and atrophy (0·74, 0·59-0·94). Risk of symptomatic intracerebral haemorrhage was increased by the presence of old infarcts (odds ratio 1·72, 95% CI 1·18-2·51), hypoattenuation (1·54, 1·04-2·27), and a hyperattenuated artery (1·54, 1·03-2·29). Multivariate logistic regression models including seven imaging signs showed that hyperattenuated arteries, large lesion, and leukoaraiosis each reduced the chance of a good outcome by 25-30%. Old infarcts and hyperattenuated arteries were signifi cant predictors of symptomatic intracerebral haemorrhage. However, the eff ect of alteplase on symptomatic intracerebral haemorrhage or functional outcome was not modifi ed by any of these CT variables.
3
When interpreting these fi ndings, the characteristics of patients included in IST-3 should be considered. The prevalence of tissue hypoattenuation might have been lower than in previous studies because of the large number of patients older than 80 years of age. Indeed, fi ndings from the present analysis confi rm a negative association between tissue hypoattenuation and age. Moreover, the relation between age and symptomatic intracerebral haemorrhage could be more complex than initially thought. The Safe Implementation of Thrombolysis in Stroke (SITS) registry has shown that the rate of symptomatic intracerebral haemorrhage increases with age up to 70 years, but not beyond. 4 Such a ceiling eff ect could account for why IST-3 could not confi rm the association of age with symptomatic intracerebral haemorrhage reported in previous trials that included younger patients.
5
Compared with other trials, the relatively high proportion of patients treated within 3 h in IST-3 is another likely explanation for the lack of association between tissue hypoattenuation and symptomatic intracerebral haemorrhage in multivariate analysis, because tissue hypoattenuation becomes more discernible with time from stroke onset. The association between tissue hypoattenuation and symptomatic intracerebral haemorrhage was signifi cant in previous European Cooperative Acute Stroke Study (ECASS) trials, in which patients were included up to 6 h after symptom onset, but not in the National Institute of Neurological Disorders and Stroke (NINDS) trial, in which patients were included within 3 h of symptom onset.
6,7 Wardlaw and colleagues did analyses by time windows, which suggested that hypoattenuation was associated with symptomatic intracerebral haemorrhage in patients treated 4·5-6 h after stroke but not in those treated earlier, but these fi ndings must be interpreted cautiously because of small samples and wide CIs.
Wardlaw and colleagues from the IST-3 collaborative group have identifi ed some CT imaging fi ndings that might help to estimate the risk of symptomatic intracerebral haemorrhage and reduced independence for the individual patient. However, no imaging fi ndings, either alone or in combination, were associated with a modifi ed treatment eff ect of alteplase. The primary fi ndings in IST-3 have contributed to the justifi cation of extending treatment to patients older than 80 years in clinical practice. This new analysis suggests that patients who can be treated within 4·5 h might be considered for treatment irrespective of CT fi ndings, as long as intracranial haemorrhage and established cerebral infarction have been excluded, although further studies will be needed to confi rm these fi ndings. Multiple scleros is drugs: how much bang for the buck?
Vincent Larrue
Medical progress for patients with relapsing-remitting multiple sclerosis has been truly remarkable in the past two decades. So far, 12 disease-modifying therapies (DMTs) have been approved for this disorder, although regulatory approval varies by country. Given the successful performance of these agents in the clinical trial programmes that led to their approval, one has to wonder whether any regulatory agency or insurance carrier should require proof of effi cacy beyond the regulatory approval data. In 2002, the UK's National Institute for Clinical Excellence concluded that interferon beta-1a, interferon beta-1b, and glatiramer acetate would be cost eff ective only if the short-term disability benefi ts reported in clinical trials were maintained over an extended period in clinical practice. This conclusion seems reasonable, because safety and effi cacy in trial populations are often diff erent from the results achieved in real-world clinical settings. 1 Consequently, the UK Multiple Sclerosis Risk Sharing Scheme (RSS) was established to assess whether disability progression as measured by the expanded disability status scale (EDSS) was consistent with a cost-eff ectiveness target of £36 000 per quality-adjusted life-year. In The Lancet Neurology, Jacqueline Palace and colleagues 2 report fi ndings from an analysis of eff ectiveness and costeff ectiveness of glatiramer aceteate, interferon beta-1b, and two formulations of interferon beta-1a over the fi rst 6 years of the UK's RSS. 5610 patients with relapsingremitting multiple sclerosis starting a DMT were enrolled in the scheme, of whom 4304 were included in Palace and colleagues' analysis. The researchers compared EDSS progression at 6 years with untreated EDSS progression modelled with data from the British Columbia multiple sclerosis database, using continuous Markov and multilevel models.
3 An aggregate progression ratio for utility (a measure based on EDSS scores and quality of life) for the four DMTs combined of 0·62 (62% by comparison with untreated patients, a 38% relative reduction) was used as a threshold for cost-eff ectiveness. The utility ratios were consistent with cost-eff ectiveness: the relative rate of progression for utility was 58·5% (Markov model) or 57·1% (multilevel model). Findings from the Markov model showed an EDSS progression ratio of 75·8% and the multilevel model showed an EDSS ratio of 60·0%, equivalent to a 24% and 40% relative reduction in progression, respectively. Sensitivity analyses assessing the potential for biases continued to show a benefi cial eff ect of interferon beta formulations and glatiramer acetate. The issue underlying this research is whether the benefi ts of individual drugs justify their enormous cost to health-care providers and patients. The US Census Bureau reported that US infl ation-adjusted median household income was $51 939 in 2013. The number of medically-related personal bankruptcies in the US is well above 50% of all fi lings. Families with health insurance reported average out-of pocket medical expenses of $17 749, whereas uninsured individuals averaged $26 971. In the USA, multiple sclerosis has the highest personal drug costs of any chronic disorder, an average of US$34 167 per year for each patient in 2009 (when the yearly price of DMTs was between $22 272 and $33 804). 4, 5 Prices have doubled or even tripled for some DMTs since 2009. Although the number of treatments has increased, this change has not led to the increased competition and thus decreased prices that might be expected from economics lessons on free-market capitalism. We are currently unable to assess the merits of a less expensive drug for, say, less severe disease, because nearly all agents are roughly the same price, irrespective
